Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1 α inhibition, and hypoxia-activated chemotherapy
Oncotarget. 2024 Feb 8;15:123. doi: 10.18632/oncotarget.28560.NO ABSTRACTPMID:38329733 | PMC:PMC10852056 | DOI:10.18632/oncotarget.28560 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Changhwan Yoon Kevin K Chang Jun Ho Lee William D Tap Charles P Hart M Celeste Simon Sam S Yoon Source Type: research
Retraction: Long noncoding RNA TUG1 is a diagnostic factor in lung adenocarcinoma and suppresses apoptosis via epigenetic silencing of BAX
Oncotarget. 2024 Feb 5;15:90. doi: 10.18632/oncotarget.28462.NO ABSTRACTPMID:38329724 | PMC:PMC10852066 | DOI:10.18632/oncotarget.28462 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Huan Liu Guizhi Zhou Xin Fu Haiyan Cui Guangrui Pu Yao Xiao Wei Sun Xinhua Dong Libin Zhang Sijia Cao Guiqin Li Xiaowei Wu Xu Yang Source Type: research
Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis
Oncotarget. 2024 Feb 5;15:91-103. doi: 10.18632/oncotarget.28512.ABSTRACTAbout 7% of all cancer deaths are caused by pancreatic cancer (PCa). PCa is known for its lowest survival rates among all oncological diseases and heterogenic molecular profile. Enormous amount of genetic changes, including somatic mutations, exceeds the limits of routine clinical genetic laboratory tests and further stagnates the development of personalized treatments. We aimed to build a mutational landscape of PCa in the Russian population based on full exome next-generation sequencing (NGS) of the limited group of patients. Applying a machine lear...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: P A Shatalov N A Falaleeva E A Bykova D O Korostin V A Belova A A Zabolotneva A P Shinkarkina A Yu Gorbachev M B Potievskiy V S Surkova Zh V Khailova N A Kulemin Denis Baranovskii A A Kostin A D Kaprin P V Shegai Source Type: research
GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells
Oncotarget. 2024 Feb 8;15:124-133. doi: 10.18632/oncotarget.28557.ABSTRACTGZ17-6.02, composed of curcumin, harmine and isovanillin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with an RP2D of 375 mg PO BID. The biology of GZ17-6.02 in malignant T cells and in particular those derived from mycosis fungoides (MF) patients, has not been studied. GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells. All three components are necessary for optimal killing of MF cells. GZ17-6.02 activated ATM, the AMPK, NFκB and PERK and inactivated ERK1/2, AKT, ULK1, ...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Michael R Booth Laurence Booth Jane L Roberts Cameron West Paul Dent Source Type: research
Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
Oncotarget. 2024 Feb 5;15:104-105. doi: 10.18632/oncotarget.28536.NO ABSTRACTPMID:38329729 | PMC:PMC10852055 | DOI:10.18632/oncotarget.28536 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Yunfei Liao Lulu Chen Yong Feng Jacson Shen Yan Gao Gregory Cote Edwin Choy David Harmon Henry Mankin Francis Hornicek Zhenfeng Duan Source Type: research
Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland
In conclusion, NTRK gene fusion is infrequent in patients with PTC. Linkage of biobank samples to EHRs is feasible in describing the characteristics and outcomes of patients with PTC and potentially other cancer types.PMID:38329731 | PMC:PMC10852057 | DOI:10.18632/oncotarget.28555 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Wei Zhang Arndt A Schmitz Roosa E Kallionp ää Merja Per älä Niina Pitk änen Mikko Tukiainen Erika Alanne Korinna J öhrens Renate Schulze-Rath Bahman Farahmand Jihong Zong Source Type: research
Combining causal and correlative approaches to discover biomarkers of response to paclitaxel
Oncotarget. 2024 Feb 8;15:117-122. doi: 10.18632/oncotarget.28549.ABSTRACTWe recently discovered a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment. To further evaluate the potential application of this biomarker in the clinic for patients with glioblastoma, a prospective validation in cohorts of patients with glioblastoma is essential and will be performed as part of our ongoing phase II clinical trial (NCT04528680). The val...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Alberto Moscona-Nissan Karl J Habashy Victor A Arrieta Adam M Sonabend Crismita Dmello Source Type: research
Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1 α inhibition, and hypoxia-activated chemotherapy
Oncotarget. 2024 Feb 8;15:123. doi: 10.18632/oncotarget.28560.NO ABSTRACTPMID:38329733 | PMC:PMC10852056 | DOI:10.18632/oncotarget.28560 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Changhwan Yoon Kevin K Chang Jun Ho Lee William D Tap Charles P Hart M Celeste Simon Sam S Yoon Source Type: research
Retraction: Long noncoding RNA TUG1 is a diagnostic factor in lung adenocarcinoma and suppresses apoptosis via epigenetic silencing of BAX
Oncotarget. 2024 Feb 5;15:90. doi: 10.18632/oncotarget.28462.NO ABSTRACTPMID:38329724 | PMC:PMC10852066 | DOI:10.18632/oncotarget.28462 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Huan Liu Guizhi Zhou Xin Fu Haiyan Cui Guangrui Pu Yao Xiao Wei Sun Xinhua Dong Libin Zhang Sijia Cao Guiqin Li Xiaowei Wu Xu Yang Source Type: research
Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis
Oncotarget. 2024 Feb 5;15:91-103. doi: 10.18632/oncotarget.28512.ABSTRACTAbout 7% of all cancer deaths are caused by pancreatic cancer (PCa). PCa is known for its lowest survival rates among all oncological diseases and heterogenic molecular profile. Enormous amount of genetic changes, including somatic mutations, exceeds the limits of routine clinical genetic laboratory tests and further stagnates the development of personalized treatments. We aimed to build a mutational landscape of PCa in the Russian population based on full exome next-generation sequencing (NGS) of the limited group of patients. Applying a machine lear...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: P A Shatalov N A Falaleeva E A Bykova D O Korostin V A Belova A A Zabolotneva A P Shinkarkina A Yu Gorbachev M B Potievskiy V S Surkova Zh V Khailova N A Kulemin Denis Baranovskii A A Kostin A D Kaprin P V Shegai Source Type: research
GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells
Oncotarget. 2024 Feb 8;15:124-133. doi: 10.18632/oncotarget.28557.ABSTRACTGZ17-6.02, composed of curcumin, harmine and isovanillin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with an RP2D of 375 mg PO BID. The biology of GZ17-6.02 in malignant T cells and in particular those derived from mycosis fungoides (MF) patients, has not been studied. GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells. All three components are necessary for optimal killing of MF cells. GZ17-6.02 activated ATM, the AMPK, NFκB and PERK and inactivated ERK1/2, AKT, ULK1, ...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Michael R Booth Laurence Booth Jane L Roberts Cameron West Paul Dent Source Type: research
Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
Oncotarget. 2024 Feb 5;15:104-105. doi: 10.18632/oncotarget.28536.NO ABSTRACTPMID:38329729 | PMC:PMC10852055 | DOI:10.18632/oncotarget.28536 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Yunfei Liao Lulu Chen Yong Feng Jacson Shen Yan Gao Gregory Cote Edwin Choy David Harmon Henry Mankin Francis Hornicek Zhenfeng Duan Source Type: research
Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland
In conclusion, NTRK gene fusion is infrequent in patients with PTC. Linkage of biobank samples to EHRs is feasible in describing the characteristics and outcomes of patients with PTC and potentially other cancer types.PMID:38329731 | PMC:PMC10852057 | DOI:10.18632/oncotarget.28555 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Wei Zhang Arndt A Schmitz Roosa E Kallionp ää Merja Per älä Niina Pitk änen Mikko Tukiainen Erika Alanne Korinna J öhrens Renate Schulze-Rath Bahman Farahmand Jihong Zong Source Type: research
Combining causal and correlative approaches to discover biomarkers of response to paclitaxel
Oncotarget. 2024 Feb 8;15:117-122. doi: 10.18632/oncotarget.28549.ABSTRACTWe recently discovered a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment. To further evaluate the potential application of this biomarker in the clinic for patients with glioblastoma, a prospective validation in cohorts of patients with glioblastoma is essential and will be performed as part of our ongoing phase II clinical trial (NCT04528680). The val...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Alberto Moscona-Nissan Karl J Habashy Victor A Arrieta Adam M Sonabend Crismita Dmello Source Type: research
Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1 α inhibition, and hypoxia-activated chemotherapy
Oncotarget. 2024 Feb 8;15:123. doi: 10.18632/oncotarget.28560.NO ABSTRACTPMID:38329733 | PMC:PMC10852056 | DOI:10.18632/oncotarget.28560 (Source: Oncotarget)
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Changhwan Yoon Kevin K Chang Jun Ho Lee William D Tap Charles P Hart M Celeste Simon Sam S Yoon Source Type: research
